Scoping Study in Q3, page-37

As shown below, at the end of the June Q, Rox had $4.441M in cash which at the Q2 rate of expenditure would fund 1.9 Quarters going forward, Rox adds that the cash flows will not continue in the short term so Rox has funding for all of 2022 imo
8.8.2 Rox explains that their Scoping Study that will progress early cash flow opportunities will allow the Company to raise further funding.
Clearly, Rox sees the Scoping Study as likely to re rate the Rox share price and attract investors.
Given that instos such as Hawke's Point paid 4 cps it is unlikely that Rox will offer any insto more shares below that share price.IMO
Rox is likely to raise money by way of a rights issue to existing holders, retail and insto.
Taking up the offer at a discount to the SP (which should be much higher than at present) will ensure our holdings are not diluted.
The Scoping Study is due in the current quarter.




My opinion DYOR